Personalized medicine with a genomic twist
By W. Gregory Feero
As a primary care provider, I am a bit skeptical of those who suggest that the concept of “personalized medicine” is new. Every day we sit down with our patients, listen to their concerns, make diagnoses, and attempt to tailor treatment to our patient’s physical and psychosocial needs. In short, we personalize medicine. But do we really do this as well as we might? Though we rationalize our medication choices to ourselves and our patients, in the end, much of how we prescribe medicine relies on trial and error. This is inefficient and, all too often, dangerous.
The new vision of personalized medicine as touted today by academia, industry and others could probably be better thought of as “genomically personalized medicine.” In many ways, this vision truly represents a revolution in healthcare. A central axiom of the movement is the concept of ‘the right drug at the right dose for the right person at the right time.’
To illustrate the axiom, consider the following simple example. Assume you have a patient with a certain diagnosis who can be effectively treated with either of two drugs. However, some drugs, such as codeine, are toxic if not metabolized effectively. Today, you have no idea how the patient might respond. Or, without knowing, you might choose one drug because it happens to be generic. Now consider the value of knowing a priori through genetic testing whether a pregnant or nursing mother will under- or overmetabolize codeine, or if a patient would react poorly to a generic medicine. Given the toxicity, this knowledge would dictate your choice, thereby avoiding harm and expense. Powerful stuff.
Advances in pharmacogenomics—the science of studying how genetics and genetic variation influence drug therapy—are rapidly narrowing the gap between vision and reality. Already, specialty medicine is using FDA-approved tests such as the UGT1A1 gene assay (which measures ability to metabolize the chemotherapeutic irinotecan) to make more rational drug choices.
Primary care won’t be far behind. This is perhaps best illustrated by current clinical trials that are examining whether preemptive genetic testing for the ability to metabolize warfarin improves outcomes in patients requiring oral anticoagulation. As many readers know too well, warfarin has frustrated health care providers for many years, largely because of its narrow therapeutic index, high toxicity (devastating bleeding events) and wide variability in patient response to a given dose. Over the last several years, it has been shown that knowledge of variations in two genes (CYP2C9 and VKORC) can allow accurate prediction of warfarin metabolism, and that this prediction can effectively guide selection of the starting dose.
As well, genetic testing technology has advanced so much that point-of-care analysis of an individual’s genes affecting metabolism is feasible. Many have speculated that such testing may not only greatly reduce the burden of suffering associated with the use of warfarin, but also create a health care cost savings. Given the potential cost of introducing this technology into mainstream healthcare, others have been less sanguine.
Ongoing trials examine whether incorporating genetic test results into warfarin management protocols enhances outcomes (less time out of international normalized ratio range, fewer adverse events) when compared to standard of care and, to some degree, the cost impact. Results from these trials will likely be out before the year’s end. Similar clinical trials are underway that look at whether genetic testing that predicts selective serotonin re-uptake inhibitor metabolism improves clinical outcome.
In reality, using genetic information to predict how patients will metabolize currently available drugs is only a single facet of personalized medicine. In a somewhat longer time frame (perhaps in the next 10 years) primary care providers will likely be able to use at least a few drugs that target the molecular consequences of a patient’s disease-causing gene variants. Fantasy? No, this is already true for the choice of herceptin in breast cancer therapy. An increasingly sophisticated form of “personalized medicine” is here to stay.
W. Gregory Feero, MD, PhD, a family physician with a doctorate in human genetics, is senior adviser for genomic medicine in the Office of the Director at the NIH’s National Human Genome Research Institute.
Internist Archives Quick Links
Sign-up for Physician & Practice Timeline® text alerts and never miss another regulatory deadline!
Triggered text alerts aimed at keeping you on top of upcoming deadlines and details related to regulatory, payment, and delivery system requirements are available FREE of charge!
See sign-up instructions.
Pre-order MKSAP17 Complete and Save 15%!
Enter priority code PR58 when ordering. Limited time only. Order now.